Skip to main content
. Author manuscript; available in PMC: 2025 May 2.
Published in final edited form as: Clin Cancer Res. 2021 Mar 25;27(11):3234–3242. doi: 10.1158/1078-0432.CCR-20-3635

Table 2.

Comparison of immunotherapy-related markers between DDR-MT and DDR-WT

All MSS/pMMR MSI-H/dMMR
DDR-MT
(N = 1290)
DDR-WT
(N = 8031)
P-value DDR-MT
(N = 829)
DDR-WT
(N = 7873)
P-value DDR-MT
(N = 456)
DDR-WT
(N = 141)
P-value
TMB (Mean) 20.9/Mb 7.7/Mb < .001 13.7/Mb 7.6/Mb .02 54.5/Mb 27.8/Mb < .001
TMB-H
(≥17/Mb)
38.1% 2.1% < .001 5.6% 0.6% < .001 97.1% 84.1% < .001
TMB-H
(≥10/Mb)
52.3% 20.7% < .001 26.3% 19.4% < .001 99.3% 94.2% < .001
PD-L1 ≥5% 10.1% 2.7% < .001 4.8% 2.4% < .001 19.8% 20.4% .87

Abbreviations: DDR, DNA damage response; dMMR, mismatch repair deficient; MSI-H, microsatellite instability high; MSS, microsatellite stable; MT, mutant; pMMR, mismatch repair proficient; TMB, tumor mutation burden; TMB-H, tumor mutation burden high; WT, wild type.